To improve the discovery and advancement of innovative cancer therapeutics, the Case Comprehensive Cancer Center is providing seed funding for the development of drug screening assays within the Small Molecule Drug Development Shared Resource (SMDD). This RFA is open to all Case CCC Members and applications will be accepted immediately on a rolling basis until all pilot award slots (5) are filled. Assay development within the SMDD will transpire in two distinct phases:
Phase I: Assay Development
Up to 5 projects will be selected for assay development within the SMDD in collaboration with Yuriy Federov, Managing Director of the Shared Resource.
Potential drug targets must be justified and functionally validated by the PI.
- Assay development can transpire over a period of one year.
- The award will cover up to $10,000 of SMDD facility services for each awardee. Funds will be distributed directly to SMDD.
Phase II: High-throughput Screening
Based on potential screening robustness, up to 2 projects (from the group of Phase I awardees) will be selected for high-throughput library screening within the SMDD.
Phase II funds (up to $50,000 per awardee) will be allocated for expenses occurred for high-throughput screening within SMDD, and for laboratory-based validation analyses.
Up to 5 research projects will be funded for Phase I, with 2 research project moving forward for Phase II. Total funds committed to this RFA are $150,000.
Each Phase I research project can request services of up to $10,000 for one year, while selected Phase II research projects can request services of up to $50,000 for one year.
Open to all Case CCC members
Potential drug targets must be justified and supported by compelling validation studies to be deemed responsive for this RFA
- While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI
Open immediately and until all Phase I projects are awarded.
Contact firstname.lastname@example.org or John Pounardjian at 216.368.0846 with any questions.